Abstract: A system including a user interface that includes a processor in communication with a display and an input interface, the processor programmed to output on the display the user interface including a keyboard layout, wherein the keyboard layout includes at least a keyboard includes a collection of characters, in response to a first input from the input interface, output a first portion of the keyboard layout associated with a first subset of characters of the keyboard layout, wherein the first subset does not include all of the characters, in response to a second input from the input interface, select a second subset of characters, wherein the second subset of characters is from and include less characters than the first subset of characters and the second subset includes two or more characters, and output a character on a text field associated with the user interface based on the selection of the second subset.

Abstract: A virtual reality apparatus that includes a display configured to output information related to a user interface of the virtual reality device, a microphone configured to receive one or more spoken word commands from a user upon activation of a voice recognition session, an eye gaze sensor configured to track eye movement of the user, and a processor programmed to, in response to a first input, output one or more words of a text field, in response to an eye gaze of the user exceeding a threshold time, emphasize a group of one or more words of the text field, toggle through a plurality of words of only the group utilizing the input interface, in response to a second input, highlight and edit an edited word from the group, and in response to utilizing contextual information associated with the group a language model, outputting one or more suggested words.

Abstract: A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor -based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: Provided are tumor-activated alloreactive or xenoreactive T cells that are active only at the tumor sites and methods for the generation of tumor-activated alloreactive or xenoreactive T cells. Also provided are methods for using these tumor-activated alloreactive or xenoreactive T cells to treat tumors and cancers. The alloreactivity or xenoreactivity of the T cells at the tumor sites leads to the killing of tumor cells and stromal cells that express mismatched HLA molecules. The lack of activity of these T cells at non-tumor locations prevents attack on normal tissues. Further related methods and products are provided.

Abstract: The present disclosure provides a low plasma generation system. In one implementation, the system includes a plurality of electrodes with a grounded electrode and at least one high-voltage electrode. The grounded and the high-voltage electrodes are arranged such that a tip of the grounded electrode and a tip of the at least one high-voltage electrode have a vertical-level difference.

Abstract: A chimeric antigen receptor (CAR) contains a human Fc?RI? extracellular domain or a mutant Fc?RI? extracellular domain that has a reduced binding affinity for human IgE compared to wild type human Fc?RI? extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: The present disclosure provides a low plasma generation system. In one implementation, the system includes a plurality of electrodes with a grounded electrode and at least one high-voltage electrode. The grounded and the high-voltage electrodes are arranged such that a tip of the grounded electrode and a tip of the at least one high-voltage electrode have a vertical-level difference.

Abstract: A chimeric antigen receptor (CAR) contains a human Fc?RI? extracellular domain or a mutant Fc?RI? extracellular domain that has a reduced binding affinity for human IgE compared to wild type human Fc?RI? extracellular domain. The CAR further contains an intracellular signaling domain comprising at least one immunoreceptor-based activation motif (ITAM). The CAR may further comprise a costimulatory signaling domain, such as an intracellular domain of at least one of the costimulatory molecules 4-1BB, CD27, CD28, CD134 or ICOS. T cells transduced with vectors encoding the CAR are used in CAR-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: A chimeric antigen receptor specific for the extracellular membrane-proximal domain (EMPD) of membrane-bound IgE (mIgE) is provided. The EMPD-specific chimeric antigen receptor comprises an extracellular ligand binding domain capable of binding EMPD, a transmembrane domain, and an intracellular domain that mediates T cell activation upon EMPD binding. Nucleic acids and vectors encoding the EMPD-specific chimeric antigen receptor are provided. T cells transduced with such vectors find use in chimeric antigen receptor-based adoptive T-cell therapy for targeting IgE-expressing B cells and treating IgE-mediated allergic diseases.

Abstract: Fluid planar lipid layer-based membrane-anchored ligand systems with defined ligand valency and methods of use thereof are provided.